Health Care [ 4/12 ] | Biotechnology [ 18/72 ]
NASDAQ | Common Stock
Precision BioSciences, Inc., a clinical stage gene editing company, develops ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and in vivo therapies for genetic and infectious diseases in the United States.
The company offers ARCUS, a genome editing platform to cure genetic disorders.
It also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, an azercabtagene zapreleucel, for the treatment of acute lymphoblastic leukemia and B-cell precursor acute lymphoblastic leukemia; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T cell candidate targeting B-cell maturation antigen for relapsed or refractory (R/R) multiple myeloma in combination with nirogacestat, a gamma secretase inhibitor.
The company has development and commercial license agreements with Les Laboratoires Servier to develop allogeneic CAR T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; and Novartis Pharma AG to discover and develop in vivo gene editing products.
Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 13, 24 | -0.35 Decreased by -52.17% | -1.91 Increased by +81.68% |
| Mar 27, 24 | -4.06 Decreased by -1.46 K% | -2.05 Decreased by -98.05% |
| Nov 7, 23 | -0.07 Increased by +68.18% | -0.16 Increased by +56.25% |
| Aug 4, 23 | -0.10 Increased by +78.26% | -0.24 Increased by +58.33% |
| May 9, 23 | -0.23 Increased by +50.00% | -0.23 |
| Mar 9, 23 | -0.26 Increased by +50.00% | -0.21 Decreased by -23.81% |
| Nov 8, 22 | -0.22 Decreased by -15.79% | -0.26 Increased by +15.38% |
| Aug 8, 22 | -0.46 Decreased by -227.78% | -0.41 Decreased by -12.20% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 13.12 M Increased by +78.19% | -8.08 M Increased by +67.63% | Decreased by -61.58% Increased by +81.84% |
| Jun 30, 23 | 19.79 M Increased by +418.04% | -11.89 M Increased by +63.38% | Decreased by -60.09% Increased by +92.93% |
| Mar 31, 23 | 8.78 M Increased by +164.70% | -23.56 M Increased by +18.74% | Decreased by -268.31% Increased by +69.30% |
| Dec 31, 22 | 10.60 M Increased by +67.19% | -36.49 M Decreased by -63.69% | Decreased by -344.28% Increased by +2.09% |
| Sep 30, 22 | 7.36 M Decreased by -69.37% | -24.96 M Decreased by -121.31% | Decreased by -339.02% Decreased by -622.46% |
| Jun 30, 22 | 3.82 M Decreased by -94.45% | -32.47 M Decreased by -249.93% | Decreased by -849.97% Decreased by -2.80 K% |
| Mar 31, 22 | 3.32 M Decreased by -79.71% | -28.99 M Decreased by -55.12% | Decreased by -873.98% Decreased by -664.55% |
| Dec 31, 21 | 6.34 M Decreased by -28.34% | -22.29 M Increased by +4.96% | Decreased by -351.63% Decreased by -32.63% |